We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agilent Technologies Signs Exclusive Supply Agreement with LipoScience
News

Agilent Technologies Signs Exclusive Supply Agreement with LipoScience

Agilent Technologies Signs Exclusive Supply Agreement with LipoScience
News

Agilent Technologies Signs Exclusive Supply Agreement with LipoScience

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agilent Technologies Signs Exclusive Supply Agreement with LipoScience"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The analyzer is the first fully-automated NMR diagnostic platform designed specifically for the clinical laboratory and cleared by the U.S. Food and Drug Administration.

The Vantera Clinical Analyzer combines proprietary signal-processing algorithms and NMR spectroscopic detection to identify and quantify concentrations of lipoproteins and, potentially, small-molecule metabolites.

"We are extraordinarily pleased to join forces with LipoScience to provide key components for this leading-edge diagnostic platform," said Nick Roelofs, president of Agilent's Life Sciences Group.

"LipoScience is pioneering a new field of personalized diagnostics based on NMR technology. Broadening access to our proprietary diagnostic tests is central to our vision of becoming a clinical standard of care. We value Agilent's NMR expertise and look forward to partnering with them in our efforts to decentralize our NMR clinical analyzer to leading clinical laboratories and academic centers of excellence," added Richard O. Brajer, chief executive officer of LipoScience.

Advertisement